Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide in Hypokalemic Periodic Paralysis
NCT02582476Phase 2Terminated
- Sponsor
- University College London
- Start
- Jan 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bumetanide in hypokalemic periodic paralysis (HypoPP), sponsored by University College London. Started Jan 2015; status: terminated.
02
Drugs
bumetanide
03
Conditions
hypokalemic periodic paralysis (HypoPP)
Beyond the preview
Go deeper on NCT02582476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582476.